VISIPAQUE 270 Dosage & Rx Info | Uses, Side Effects

Visipaque 270 Generic Name & Formulations

Legal Class

General Description

Iodixanol 550mg/mL; soln for inj; contains sodium 1.87mg/mL, organically bound iodine 270mg/mL; preservative-free.

Pharmacological Class

Radiographic contrast medium.

How Supplied

Bottles (50mL, 100mL, 150mL, 200mL)—10

Manufacturer

GE Healthcare

Generic Availability

YES

Mechanism of Action

Intravascular injection of iodixanol opacifies vessels in the path of flow of the contrast agent, permitting visualization of internal structures.

Visipaque 270 Indications

Indications

Intra-arterial: Digital subtraction angiography. IV: CT imaging of the head and body, excretory urography, and peripheral venography.

Visipaque 270 Dosage and Administration

Adult

≥12yrs: Usual single doses: Intra-arterial (digital subtraction angiography): Renal arteries: 10–25mL; Aortography: 20–50mL; Major branches of aorta: 5–30mL; max 250mL. IV: CT of head or body: 75–150mL or 100–150mL bolus infusion; max 150mL. Excretory urography (normal renal function): 1mL/kg; max 100mL. Venography (per lower extremity): 50–150mL; max 250mL.

Children

<12yrs: IV: CT or excretory urography: 1–2mL/kg; max 2mL/kg.

Visipaque 270 Contraindications

Contraindications

Intrathecal use.

Visipaque 270 Boxed Warnings

Boxed Warning

Not for intrathecal use.

Visipaque 270 Warnings/Precautions

Warnings/Precautions

Have resuscitation equipment and trained personnel available. Homocystinuria: avoid. Severe renal impairment. Cardiovascular disease. CHF. Diabetes. Advanced vascular disease. Multiple myeloma/paraproteinaceous diseases. Pheochromocytoma. Catecholamine-secreting paragangliomas. Thyroid dysfunction (esp. children 0–3yrs); monitor. Homozygous sickle cell disease. History of severe cutaneous adverse reactions: avoid. Maintain adequate hydration. Avoid extravasation. Children: asthma, cyanotic and acyanotic heart disease, CHF, serum creatinine >1.5mg/dL, immature renal function, dehydration: increased risk of adverse effects. Elderly. Pregnancy. Nursing mothers: not recommended.

Visipaque 270 Pharmacokinetics

Distribution

Volume of distribution: 0.26 L/kg body weight in adults.

Elimination

Renal (97%), fecal (<2%).
Half-life: 2.1 hours (adults).

Visipaque 270 Interactions

Interactions

May increase risk of metformin-induced lactic acidosis. Recently received cholecystographic agents in patients with hepatic or biliary disorder; increased risk of renal toxicity. Do not mix with other drugs. Caution with concomitant beta-blockers. Do not use laxatives, diuretics, or preparatory dehydration prior to administration. Radioactive iodine uptake studies may not accurately reflect thyroid function for at least 16 days.

Visipaque 270 Adverse Reactions

Adverse Reactions

Rash, erythema, pruritus, scotoma; acute kidney injury, thromboembolic events, hypersensitivity reactions, others.

Visipaque 270 Clinical Trials

See Literature

Visipaque 270 Note

Not Applicable

Visipaque 270 Patient Counseling